AGEN
What one share of Agenus holds
Biological Products, (No Diagnostic Substances)
Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy.
Agenus’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.62 |
|---|---|
| Profit | $2.50 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.69 |
| Cash and investments | $0.44 |
| Debt | $0.71 |
| Book value | −$4.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $6.96 | −$15.64 | $3.77 | −$16.22 | — | — |
| 2023 | $8.74 | −$13.75 | $0.56 | −$13.09 | — | −$8.13 |
| 2024 | $4.82 | −$10.59 | $0.03 | −$7.40 | — | −$13.81 |
| 2025 | $3.84 | −$0.00 | $0.00 | −$2.60 | — | −$7.68 |